Skip to main content

Third Wave Stock Dives 13 Percent on Disappointing Q3 Results

NEW YORK, Nov. 2 (GenomeWeb News) - Shares in Third Wave were down 13.2 percent, or $.47, at $3.08 in mid-afternoon trading after the company announced this morning that  third-quarter revenue fell by half and net losses grew more than 300 fold.

 

As GenomeWeb News reported earlier today, Third Wave's blamed its revenue decline on a "reduction in non-recurring research revenue from Japan." It also said that growth related to molecular diagnostics has been "flat."

 

Separately today, research firm Caris & Company downgraded the stock to "Below Average" from "Average."

The Scan

Gap in COVAX Doses

BBC News reports that COVAX is experiencing a vaccine shortfall, as the Serum Institute of India has paused exports.

Sanofi, GSK Report Promising Results

The Wall Street Journal reports that the candidate SARS-CoV-2 vaccine from Sanofi and GlaxoSmithKline has had encouraging early results.

Influence of Luck

The New York Times examines how the US avoided variant-fueled increases in COVID-19 cases.

PLOS Papers on Retina GWAS, Hantaan Virus, COVID-19 Phenome-Wide Association Study

In PLOS this week: genome-wide association study of retinal morphology, analysis of hantaan virus found in a mouse, and more.